Sonoma Pharmaceuticals (SNOA) Stock Analysis & Winston Score

Sonoma Pharmaceuticals is a small healthcare company that makes skin and wound care products. Its core technology is a stabilized hypochlorous acid solution, sold under the Microcyn brand, which is used to clean and treat wounds, skin infections, and eye conditions. The company sells to hospitals, clinics, and consumers, and also licenses its technology to other companies that sell products under their own brand names. Sonoma makes money through product sales and licensing agreements. It operates in the United States, Europe, Latin America, and Asia, though it remains a very small company with a market cap under $100 million. Its proprietary formulation technology gives it some differentiation, but the wound care market is crowded with larger, better-funded competitors. The company is currently unprofitable, and its main challenge is scaling revenue fast enough to cover operating costs — making consistent profitability the key hurdle investors are watching.